Fc receptors are required in passive and active immunity to melanoma
Open accessAbstract
Effective tumor immunity requires recognition of tumor cells coupled with the activation of host effector responses. Fc receptor (FcR) gamma-/- mice, which lack the activating Fc gamma R types I and III, did not demonstrate protective tumor immunity in models of passive and active immunization against a relevant tumor differentiation antigen, the brown locus protein gp75. In wild-type mice, passive immunization with mAb against gp75 or active immunization against gp75 prevented the development of lung metastases. This protective response was completely abolished in FcR gamma-deficient mice. Immune responses were intact in gamma-/- mice because IgG titers against gp75 develop normally in gamma-/- mice immunized with gp75. However, uncoupling of the Fc gamma R effector pathway from antibody recognition of tumor antigens resulted in a loss of protection against tumor challenge. These data demonstrate an unexpected and critical role for FcRs in mediating tumor cytotoxicity in vivo and suggest that enhancement of Fc gamma R-mediated antibody-dependent cellular cytotoxicity by inflammatory cells is a key step in the development of effective tumor immunotherapeutics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IgG modulates cellular immune responses through FcγR-binding and direct receptor- or ligand-binding.
“They modulate cellular immune responses through Fcγ receptor (FcγR)-binding as well as through direct receptor- or ligand-binding [9,10].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [9]
Cited by
Sorted by citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works
Self-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works
Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204 · see citing works
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189 · see citing works
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37 · see citing works
- Authors
- Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-01-20
- Volume
- 95
- Issue
- 2
- Pages
- 652-656
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18475
- OpenAlex
- W2132661000
- Cited by
- 321
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 10 · 2016: 10 · 2015: 18 · 2014: 10 · 2013: 9 · 2012: 16
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swim Across America
- National Institutes of Health (5k08dk002468-02)
- National Cancer Institute (R01 CA56821, R01CA056821)
- National Institute of Allergy and Infectious Diseases (R01AI35875, R01AI035875)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK02468)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- Fc receptors, Fc gamma receptor, melanoma, antitumor immunity, passive immunization, active immunization, antibody-dependent cellular cytotoxicity, lung metastasis, cancer immunotherapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Immunity, Immunization, Passive, Melanoma, Experimental, Membrane Glycoproteins, Mice, Inbred C57BL, Oxidoreductases, Proteins, Receptors, Fc, Vaccination, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
